QPS, a Taiwan-based global contract research organisation, announced on Tuesday that it has opened a second preclinical research facility in Taipei, Taiwan.

The facility covers 2,793-square-foot area and will facilitate a research expansion into additional toxicology studies and a newly launched capability in pharmacology studies.

The company is to commence operations of the new facility in December 2022 and said that it will offer significant additional flexibility in study scheduling and additional space to increase the present toxicology business and to construct the new pharmacology unit.

The firm has named Dr Mei-Ling Hou, PhD to head the new pharmacology department.